DISCROMIAS PIGMENTARIAS PDF
Las alteraciones en el color de la piel reciben globalmente el nombre de discromías, pero dado que pueden ser debidas a un exceso o defecto. TALLER DE DISCROMÍAS PIGMENTARIAS (MANCHAS) faciales y corporales Public. · Hosted by Distribuidora Go Rosario. Interested. centro de estetica GARA – calle Ambroz 8, Vicálvaro – Rated based on 8 Reviews “Agradables te hacen la depilación genial OS la recomiendo. La.
|Published (Last):||11 April 2018|
|PDF File Size:||9.53 Mb|
|ePub File Size:||17.57 Mb|
|Price:||Free* [*Free Regsitration Required]|
It has been monitored the skin condition from the initial state observed during the study entry, pigmemtarias the dermatologist after 60 days of use of the tested product. The results correspond to the mean and deviations from the mean – SEM are indicated in Tables 4 and 5 below. Protocolo de indicaciones de biopsia sinovial.
The skin of the tested people is protected from sunlight by applying full protection SPF Pitiriasis alba Dartros 2. Protocolo de quimioprofilaxis de la tuberculosis.
Discromías by Diana Sanders on Prezi
Each treatment condition was performed in triplicate. Furthermore, it is necessary to expose and remove the factor inducing hyperpigmentation before treating UV, perfume, estroprogestativo and advise a pigmentarixs maximum over protection type medical monitoring. The reasons that push discolor the skin may be different.
Mask of pregnancy or chloasma, appears in women who have an important percentage of female hormones and whose skin is exposed to the sun. Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent. Use according to any of the preceding claims, wherein the composition further comprises at least one organic or mineral sun filter.
Enfermedad del pelo de acero de Menkes Amiodarona 5. The D60 has been carried out a questionnaire on the subject in relation to the cosmetic qualities of the product tested.
Ejemplo 3 example 3. The average results observed for healthy skin control are: Surprisingly, we have now demonstrated that oxazolines also exhibit depigmenting action.
IBMX 3-isobutylmethylxanthine, reference molecule pro-pigmenting. The present invention relates to the use of a cosmetic composition having depigmenting action dlscromias lightening skin, comprising, as active principle, at least one oxazoline.
Los resultados medios observados para las zonas hiperpigmentadas tratadas son los siguientes: Int J Paediatr Dent. Ejemplo 1 Example 1.
It has made an assessment of the oigmentarias tolerance the D60 according to a severity scale of 4 levels. The composition is advantageously as defined above.
Depigmenting or lightening cosmetic composition comprising at least one oxazoline as active principle. Process according pimgentarias claim 10, characterized in that the pigmentation spots are age spots few, or a sunspots, or a related stains phototoxicity or chloasma few.
The results of the statistically significant after 6 weeks of application, some of the criteria evaluated variation are indicated in the following table 6: The composition used according to the invention may contain other active agents having depigmenting action, causing a complementary or synergistic effect.
OX may have therefore a clear effect normal skin. Pigmentarixs the form of brown pigmented plaques, often symmetrical, more or less regular basis. They act on the formation, transport, the color of melanin itself or on the viability of melanocytes melanocitotoxicidad. The following examples illustrate the present invention.
The calculation used has been simplified MASI, ie: They have served for the precise location of the hyperpigmented areas. Eventually, it can be applied to the skin in aerosol form. In addition, the melanin index measured on a healthy area normally pigmented skin in order to have a reference base. The difference between the measurements T1 is Cytotoxicity by an MTT assay tetrazolium salt and a morphological observation of the cells.
Clinical manifestations and treatment of Menkes disease and its variants. In the French patent application FR 2,, the inventors describe the use of oxazolines, allowing inhibition of migration of Langerhans cells. The composition according to the invention may also contain adjuvants that are common in the cosmetics field, such as stabilizers, preservatives, antioxidants, solvents, perfumes, chelating agents, odor absorbers, some chemical filters or minerals, a mineral pigments, surfactants, polymers, silicone oils and dyestuffs.